Mirum Pharmaceuticals, Inc. shows strong growth with a 43% revenue jump and promising pipeline assets. Click here for my ...

Mirum Pharmaceuticals’ MIRM lead product, Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) ...

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

A research team has made further progress in the treatment of intestinal inflammation. A study shows that the semi-synthetic bile acid NorUDCA inhibits in the intestine the formation of ...

A research team from the Medical University of Vienna has made further progress in the treatment of intestinal inflammation.

H.C. Wainwright raised the firm’s price target on ProQR Therapeutics (PRQR) to $12 from $10 and keeps a Buy rating on the shares. The firm says ...

Aim: The issue of transplant-free survival rate (OS) among patients with primary biliary cholangitis (PBC) remains a persistent concern. In predicting the long-term OS of PBC patients, given the ...

Bexotegrast has has received fast track and orphan drug tags from the FDA in IPF and primary sclerosing cholangitis (PSC), and is Pliant’s most clinically advanced asset. Since the ...

François-Philippe Champagne, Minister of Innovation, Science and Industry "We are grateful for how the Conscience grant is supporting Primary Sclerosing Cholangitis (PSC) research. PSC is a rare ...

Other causes for a lier transplant include diseases that affect bile ducts that carry bile from the liver, such as biliary cirrhosis, primary sclerosing cholangitis and biliary atresia.